top of page

SURMOUNT-1 trial

The SURMOUNT-1 trial was the world's first large-scale clinical trial of tirzepatide (Zepbound).

The weight loss and health effects were examined over a 72-week period in obese patients without diabetes.

​Exam Overview

  • Subjects: 2,539 non-diabetic adults with a BMI of 30 or higher, or a BMI of 27 or higher and complications

  • Method: Tirzepatide (5 mg, 10 mg, 15 mg) or placebo was administered by subcutaneous injection once a week.

Key results

名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png
名称未設定のデザイン (1).png

Weight Loss Effect

10mg group: Average −17.8%

15mg group: Average −22.7%

Placebo group: −1.7%

→ Most patients achieved weight loss of approximately 20%.

 

Percentage achieving ≥5% weight loss

10mg group: 94%

15mg group: 96%

Placebo group: 20%

 

Improvement in Metabolic Parameters

HbA1c decreased by an average of 0.67%

Improvement in fasting blood glucose levels

Enhanced insulin sensitivity

 

Improvement in Cardiovascular Risk Factors

Blood pressure (systolic: decreased by approximately 11-12 mmHg)

Triglycerides (reduced by approximately 50%)

Decreased uric acid levels

 

Improved body fat

Visceral fat: Approximately 40% or more reduction

Subcutaneous fat: Approximately 30% or more reduction

Significant improvement in hepatic fat (Fatty liver improvement rate around 70%)

 

Patient Quality of Life (QOL)

Significant improvement in scores related to physical function and quality of life

bottom of page